Is Viatris Stock Underperforming the Dow? Viatris has underperformed the Dow Jones Industrial Average over the past year, and analysts remain cautious about the stock’s prospects. Barchart · Sep 23, 2024
Is Wall Street Bullish or Bearish on Viatris' Stock? Viatris has underperformed the broader market over the past year, and Wall Street analysts are cautious about the stock’s prospects. Barchart · Aug 5, 2024
Viatris Quarterly Earnings Preview: What You Need to Know Viatris is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip. Barchart · Jul 26, 2024
3 Low P/E Stocks With Strong Growth Prospects With easing inflation and possibilities of interest rate cuts, investors can rely on stocks like Viatris (VTRS), Open Text (OTEX), and Goodyear Tire & Rubber (GT) with strong growth prospects, trading at affordable prices. Keep reading. StockNews.com · Jul 24, 2024
3 Pharmaceutical Stocks With Blockbuster Potential The pharmaceutical industry’s long-term growth is fueled by a surge in demand for personalized medicine, favorable R&D initiatives, and the adoption of cutting-edge technologies. Hence, it could be ideal to buy fundamentally solid pharma stocks Zoetis (ZTS), Viatris (VTRS), and Bristol-Myers Squibb (BMY) poised for blockbuster return potential. Keep reading…. StockNews.com · Jun 21, 2024
4 Pharma Stocks to Watch for Surprising Gains in June Amid growing demand for specialty drugs and increasing adoption of emerging technology in pharmaceutical manufacturing, the pharma industry is witnessing steady expansion. Therefore, quality pharmaceutical stocks Zoetis (ZTS), Viatris (VTRS), MEI Pharma (MEIP), and Amphastar Pharmaceuticals (AMPH) could be ideal additions to your watchlist. Keep reading…. StockNews.com · May 28, 2024
Are Wall Street Analysts Bullish on Viatris Stock? Viatris has underperformed the broader market over the past year, and analysts remain cautious about the stock's prospects. Barchart · May 24, 2024
3 Top-Rated Pharma Stocks to Diversify Your Portfolio The pharmaceutical industry is expanding owing to the rising incidence of chronic diseases, increasing investments in R&D, and the use of advanced technologies for drug development and manufacturing. Given this backdrop, investors could consider buying quality pharma stocks such as Elanco Animal Health (ELAN), Viatris (VTRS), and Astellas Pharma (ALPMY),… StockNews.com · May 13, 2024
3 Pharma Stocks Outperforming the Competition The growing demand for innovative drugs, the use of advanced technologies, and growing global healthcare needs boost the pharmaceutical industry’s long-term growth prospects. Therefore, fundamentally strong pharma stocks Viatris (VTRS), Wave Life Sciences (WVE), and MEI Pharma (MEIP) might be ideal additions to your portfolio. Read on. StockNews.com · Mar 20, 2024
5 Pharma Stocks to Watch With Bullish Momentum The pharma industry is poised for robust expansion this year with rising demand and technological advancement in the sector. Hence, investors might watch fundamentally solid pharma stocks Procaps Group (PROC), Sanofi (SNY), Viatris (VTRS), Ipsen (IPSEY), and Teva Pharmaceutical Industries (TEVA) for solid gains. Read on. StockNews.com · Feb 12, 2024
3 Lucrative Pharma Stocks for Portfolio Success The pharmaceutical industry holds immense promise due to the rapidly aging population, growing healthcare needs, breakthroughs in new drugs and therapies, and the rise in chronic diseases. Therefore, it could be wise to add fundamentally strong pharma stocks Supernus Pharmaceuticals (SUPN), Eton Pharmaceuticals (ETON), and Viatris (VTRS) to one’s portfolio.… StockNews.com · Feb 2, 2024
Top 4 Pharma Picks for January 2024 Growth The pharmaceutical industry’s future is increasingly promising, spurred by a rise in healthcare expenditure amid escalating chronic and rare disease cases and a burgeoning aged population. The industry's bright outlook is also strengthened by consistent forays into research and development. Against this backdrop, quality pharma stocks Pacira BioSciences (PCRX), Eli… StockNews.com · Jan 9, 2024
Under $15 Bargains: 3 Pharma Stocks to Watch The pharmaceutical industry is anticipated to remain resilient, owing to increasing healthcare expenditure. Given this backdrop, it could be wise to watch quality pharma stocks Organon & Co. (OGN), GoodRx Holdings (GDRX), and Viatris (VTRS) trading under $15 now. Read on…. StockNews.com · Nov 17, 2023
3 Stocks to Buy With Less Than $10 The recent collapse of two banks and growing uncertainty about the Fed’s next rate hike amid the strong economic data releases fueled a broad market sell-off lately. However, a volatile market environment offers an attractive opportunity to invest in quality stocks ADT (ADT), Viatris (VTRS), and trivago (TRVG) at reasonable… StockNews.com · Mar 20, 2023
Benzinga · May 9, 2022 Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus Viatris Inc (NASDAQ:VTRS) reported Q1 FY22 sales of $4.18 billion, down 5% Y/Y (-1% on an operational basis), below the consensus of $4.23 billion. Brands performed better than expectations, such as Lipitor, Effexor, and Perforomist. Complex generics and biosimilars grew by 21% Y/Y on an operational basis, driven mainly by the generic…
Benzinga · May 4, 2022 Viatris Q1 2022 Earnings Conference Call On May 9, 2022 At 08:30 AM ET Viatris (NASDAQ:VTRS) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.
Benzinga · Apr 13, 2022 Viatris' Mylan Recalls One Batch Of Insulin Glargine Due To Missing Label Mylan Pharmaceuticals Inc, a Viatris Inc (NASDAQ: VTRS) company, is
Benzinga · Mar 1, 2022 Viatris's Return On Capital Employed Overview Benzinga Pro data, Viatris (NASDAQ:VTRS) reported Q4 sales of $4.34 billion. Earnings fell to a loss of $263.80 million, resulting in a 184.69% decrease from last quarter. Viatris earned $311.50 million, and sales totaled $4.54 billion in Q3.
Benzinga · Feb 28, 2022 Why Viatris Shares Are Trading Lower Today Viatris Inc (NASDAQ: VTRS) is trading lower Monday after the company reported worse-than-expected top-line results for the fourth quarter and issued guidance below estimates.
Benzinga · Feb 28, 2022 Viatris To Pay $264M As EpiPen Antitrust Litigation Settlement: Reuters Viatris Inc (NASDAQ: VTRS), previously known as Mylan, has
Benzinga · Feb 28, 2022 India-Based Biocon To Buy Viatris' Biosimilars Assets In $3.3B Deal Biocon Biologics Ltd has agreed to acquire Viatris Inc's (NASDAQ:VTRS) biosimilars assets for up to $3.335 billion in stock and cash. The deal value includes cash of up to $2.335 billion and Compulsorily Convertible Preference Shares in Biocon Biologics, valued at $1 billion. Viatris will also pay $50 million to Biocon Biologics to fund…
Benzinga · Feb 16, 2022 A Bullish Sign Appears On Viatris's Chart If history is any guide, there may be good fortune ahead for shares of Viatris (NASDAQ:VTRS). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.
Benzinga · Jan 20, 2022 Viatris Recalls One Batch Of Diabetes Treatment Semglee Citing Missing Label Risks Viatris Inc's (NASDAQ: VTRS) Mylan will pull one batch of non-interchangeable Semglee, also known as insulin glargine injection.